Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: A systematic review of efficacy and adverse effects

BJU International

Volumn 94, Issue 9, 2004, Pages 1263-1270

  MacDonald, Roderick ^a   Wilt, Timothy J ^a,c   Howe, R William ^b  

^a VA MEDICAL CENTER   (United States)

^b Lostwithiel Medical Practice   (United Kingdom)

^c Minneapolis VA Ctr Chron Dis O   (United States)

Author keywords

1 adrenoceptor antagonists; Benign prostatic obstruction; Doxazosin; LUTS; Systematic review

Indexed keywords

ALFUZOSIN; DOXAZOSIN; FINASTERIDE; PLACEBO; TAMSULOSIN; TERAZOSIN;

CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; URETHRA STENOSIS; URINE FLOW RATE; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; CROSS-OVER STUDIES; DOXAZOSIN; DRUG COMBINATIONS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; URINARY RETENTION;

EID: 11144248215     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.05154.x     Document Type: Review

References (23)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71
2. Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85-9
3. Kortt MA, Bootman JL. The economics of benign prostatic hyperplasia treatment: a literature review. Clin Ther 1996; 18: 1227-41
4. Barry MJ, Fowler FJ Jr, Bin L, Oesterling JE. A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol 1997; 158: 488-91
5. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 312: 944-7
6. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12
7. Anonymous. Review Manager [Computer program]. Version 4.1. For Windows. Oxford, England: The Cochrane Collaboration, 2001
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88
9. Akan H, Basar M, Dalva I, Basar H. The early effects of doxazosin on benign prostatic hyperplasia. Arch Ital Urol Androl 1998; 70: 41-4
10. Andersen M, Dahlstrand C, Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 2000; 38: 400-9
11. Chapple CR, Carter P, Christmas TJ et al. A 3-month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50-6
12. Janknegt RA, Chapple CR. Efficacy and safety of thealpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. Eur Urol 1993; 24: 319-26
13. Christensen MM, Bendix Holme J, Rasmussen PC et al. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol 1993; 27: 39-44
14. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-9
15. Gillenwater JY, Conn RL, Chrysant SG et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-5
16. Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The prospective European doxazosin and combination therapy (PREDICT) trial. Urology 2003; 61: 119-26
17. McConnell JD, Roehrborn C, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. NEJM 2003; 349: 2387-98
18. Roehrborn C, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 406-15
19. Rollema HJ, Rosier P, Janknegt RA, van Mastrigt R. Efficacy of alpha-blocker (doxazosin) in BPH appraised by pressure-flow (CLIM) analysis. Neurourol Urodynam 1991; 10: 295-9
20. de Reijke TM, Klarskov P. Comparative efficacy of two cc1-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU Int 2004; 93: 757-62
21. Kaplan SA, Soldo KA. Olsson CA. Terazosin and doxazosin in normotensive men with symptomatic prostatism:a pilot study to determine the effect of dosing regimen on efficacy and safety. Eur Urol 1995; 28: 223-8
22. Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003; 91: 41-4
23. Fulton B. Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320